Qualitis
Qualitis operates as a privately held Contract Research Organization (CRO) providing Phase I-IV clinical trial management, functional service provision, and real-world research services to pharmaceutical, biotechnology, and medical device sponsors across five therapeutic areas, with offices in Zagreb, Boston, and Chennai.
- Company typePrivate
- Founded2006
- HeadquartersAthens, Greece
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Qualitis does
Qualitis is positioned in the source data as a privately held clinical development and research services provider, with the underlying operational entity identified as Optimapharm d.o.o., a Croatian limited liability company. Note: the firmographic header lists Qualitis in Athens, Greece (website qualitis.gr, founded 2006, 51-100 employees), while the bulk of the operational data describes Optimapharm d.o.o. headquartered in Zagreb, Croatia; this discrepancy is preserved as observed rather than reconciled.
The company operates as a Contract Research Organization (CRO) delivering three core services: Full Service Phase I-IV clinical trial management, Functional Service Provision (FSP) for targeted clinical operations support, and Real World Research for observational studies and real-world evidence generation. Underlying these services are five branded therapeutic platforms — OptimaCardio (cardiology), OptimaImmuno (immunology), OptimaDerm (dermatology), OptimaOnco (oncology), and OptimaNeuro (neurology) — which the firm markets as "integrated therapeutic platforms" designed to deliver broader patient access and regulatory advantage. No proprietary software, APIs, or AI/ML systems are disclosed in the source.
The business model is enterprise professional services: custom, project-based contracts with pharmaceutical, biotechnology, and medical device sponsors, sold directly through a Request Proposal process and supported by a field sales team. Pricing is not publicly disclosed, and engagements are structured as multi-year contracts. The company maintains offices in Zagreb (global headquarters), Boston (US head office), and Chennai, India (APAC head office), and self-reports 2x the geographic reach across North America and Europe compared to the average mid-sized CRO. The company is privately held with no disclosed funding rounds, parent company, or institutional investors. No customer logos, named sponsors, patents, certifications, or M&A activity are present in the source data.
Qualitis firmographics
Firmographics- Name
- Qualitis
- Legal name
- Optimapharm d.o.o.
- Website
- https://qualitis.gr
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Qualitis operates as a privately held Contract Research Organization (CRO) providing Phase I-IV clinical trial management, functional service provision, and real-world research services to pharmaceutical, biotechnology, and medical device sponsors across five therapeutic areas, with offices in Zagreb, Boston, and Chennai.
- Ownership category
- akta.pro rank
Qualitis industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)
- akta.pro secondary industry
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
Keywords
Where Qualitis is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices3 records
Markets served
Qualitis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: Full-service Phase I-IV clinical trial management and Functional Service Provision (FSP) for pharmaceutical and biotech sponsors. Revenue generated through project-based contracts for clinical development programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Qualitis product offering
Product offeringCore offering
Qualitis (operating as Optimapharm) is a Contract Research Organization providing full-service Phase I-IV clinical trial management, Functional Service Provision (FSP), and Real World Research to pharmaceutical, biotechnology, and medical device sponsors. Services are delivered through five integrated therapeutic platforms covering cardiology, immunology, dermatitis, oncology, and neurology, with global operations spanning Croatia, the United States, and India.
Product overview
Optimapharm is a Contract Research Organization (CRO) providing integrated clinical research services. The company operates a unified service model consisting of three core offerings: Full Service Phase I-IV (comprehensive end-to-end clinical trial management), Functional Service Provision (FSP - flexible, targeted support services), and Real World Research (observational studies and real-world evidence generation). The company maintains therapeutic expertise platforms across five key areas: Cardiology (OptimaCardioSuite), Immunology (OptimaImmunoSuite), Dermatology (OptimaDermSuite), Oncology (OptimaOncoSuite), and Neurology (OptimaNeuroSuite). Optimapharm emphasizes its global reach across North America, Europe, and APAC, with operations spanning Croatia (headquarters), Boston, USA, and Chennai, India.
Differentiator
Problem solved
Functional benefit
Brands
- OptimaCardio Suite: Cardiology therapeutic platform
- OptimaImmuno Suite
- OptimaDerm Suite
- OptimaOnco Suite
- OptimaNeuro Suite
Products and services
- Full Service Phase I-IV
- Functional Service Provision (FSP) Flexible functional service provision offering targeted clinical trial support such as monitoring, data management, and regulatory affairs on a dedicated or distributed basis for sponsors that need targeted resourcing rather than full-service outsourcing.
- Real World Research Real-world evidence and observational research services that generate evidence from clinical practice settings to support regulatory submissions and market access for pharmaceutical and biotechnology sponsors.
Quantifiable outcome
- 2x more reach across North America and Europe than the average mid-sized CRO
Companies that use Qualitis
Customer profileSegments3 records
Ideal customer profiles3 records
Qualitis technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Qualitis partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
Qualitis competitors and assessment
Company assessmentBroad incumbents
- Syneos Health: Global clinical and commercial solutions provider offering full-service clinical operations, FSP, and real-world evidence. Direct overlap with Optimapharm's three core services from a much larger commercial footprint.
- ICON plc: One of the largest global CROs following the PRA Health acquisition, offering full-service, FSP, and real-world evidence across all therapeutic areas. Represents the scaled incumbent Optimapharm competes against for full-service Phase III enterprise work.
- IQVIA: Largest global CRO with proprietary technology platforms, real-world data assets, and preferred-vendor status with major pharma. Defines the upper bound of scale and capability that Optimapharm must differentiate against.
Direct peers
- Charles River Laboratories: CRO/CDMO with strong early-phase and discovery presence that has expanded into Phase II-IV clinical services. Comparable therapeutic-area emphasis (particularly CNS/oncology), giving it a similar sponsor-value proposition in biotech.
- Medpace Holdings: Mid-to-large full-service CRO operating with a therapeutic-area specialization model that mirrors Optimapharm's branded OptimaCardio/OptimaOnco suites. Both compete for biotech and mid-sized pharma Phase II-IV work, making Medpace the most size- and model-comparable peer.
- Parexel International: Global full-service and FSP CRO with broad therapeutic-area coverage and major presence in Europe and North America. Directly competes for Optimapharm's pharma and biotech sponsor RFPs across Phase I-IV and functional service contracts.
- Worldwide Clinical Trials: Mid-sized, therapeutically focused CRO emphasizing neuroscience, oncology, and immunology — overlapping heavily with Optimapharm's OptimaNeuro and OptimaOnco platforms. Comparable size, therapeutic emphasis, and sponsor mix make it a high-relevance peer.
- TFS HealthScience: European-headquartered mid-sized CRO with global delivery footprint and therapeutic-area specialization. Closest match in terms of size, geography, and operating model to Optimapharm.
Emerging players
- Clinipace Worldwide: Smaller, therapeutically focused CRO offering adaptive trial designs and full-service capabilities to mid-sized biotech. Addresses a similar sponsor segment to Optimapharm with a narrower therapeutic footprint.
- Rho (Contract Research Organization): Mid-sized full-service CRO with a clinical operations and biostatistics emphasis similar to an FSP-led delivery model. Competes for the same therapeutic-area focused mid-size biotech programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Qualitis social profiles
Digital presenceQualitis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Qualitis leadership team
Management profileNumber of profiles
Qualitis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Qualitis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Qualitis
What does Qualitis do?
Qualitis (operating as Optimapharm) is a Contract Research Organization providing full-service Phase I-IV clinical trial management, Functional Service Provision (FSP), and Real World Research to pharmaceutical, biotechnology, and medical device sponsors. Services are delivered through five integrated therapeutic platforms covering cardiology, immunology, dermatitis, oncology, and neurology, with global operations spanning Croatia, the United States, and India.
Is Qualitis a public or private company?
Qualitis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Qualitis founded?
Qualitis was founded in 2006. It employs 51 to 100 people.
Where is Qualitis based?
Qualitis is headquartered in Athens, Greece, in the Europe region.
How does Qualitis make money?
One revenue line is on record: clinical Research Services.
Who are Qualitis's main competitors?
Broad incumbents on record are Syneos Health, ICON plc and IQVIA. Direct peers are Charles River Laboratories, Medpace Holdings, Parexel International, Worldwide Clinical Trials and TFS HealthScience. Emerging players are Clinipace Worldwide and Rho (Contract Research Organization).
Does Qualitis have an API?
No public API is recorded for Qualitis.
What industry is Qualitis in?
Qualitis's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAOAA, Clinical Operations & Monitoring FSP (CRA/CTM/Start-up), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 62151 and its SIC code is 8731.